Table 1. Characteristics of men undergoing transurethral prostate surgery according to preoperative serum testosterone (normal ≥ 300 ng/dL).
A p-value <0.05 was considered statistically significant
*Five men missing hemoglobin and hematocrit values
^Twelve men missing hemoglobin and hematocrit values
1Mean ± standard deviation; n (%)
2Welch two-sample t-test; Fisher’s exact test; Pearson’s chi-squared test
HFRS, Hospital Frailty Risk Score; PVP, photovaporization of the prostate; TURP, transurethral resection of the prostate
| Low testosterone1 (n = 86)* | Normal testosterone1 (n = 89)^ | p-value2 | |
| Age at surgery | 68.7 ± 9.3 | 64.8 ± 11.8 | 0.016 |
| BMI | 28.5 ± 6.5 | 28.5 ± 5.3 | >0.9 |
| Procedure | 0.9 | ||
| TURP | 78 (91%) | 79 (89%) | - |
| PVP | 8 (9.3%) | 10 (11%) | - |
| Race | 0.2 | ||
| White | 69 (80%) | 73 (82%) | - |
| Asian | 6 (7.0%) | 1 (1.1%) | - |
| Black/African American | 7 (8.1%) | 9 (10%) | - |
| Declined/other | 4 (4.7%) | 6 (6.7%) | - |
| Ethnicity | 0.06 | ||
| Hispanic or Latino | 1 (1.2%) | 6 (6.7%) | - |
| Not Hispanic or Latino | 76 (88%) | 79 (89%) | - |
| Declined | 9 (10%) | 4 (4.5%) | - |
| ASA Class | 0.13 | ||
| 0 | 35 (41%) | 25 (28%) | - |
| 1 | 3 (3.5%) | 3 (3.4%) | - |
| 2 | 24 (28%) | 34 (38%) | - |
| 3 | 21 (24%) | 7 (30%) | - |
| 4 | 3 (3.5%) | 0 (0%) | - |
| HFRS | 10.8 ± 12.2 | 10.5 ± 10.1 | 0.9 |
| Low risk | 35 (41%) | 31 (35%) | 0.7 |
| Intermediate risk | 29 (34%) | 35 (39%) | - |
| High risk | 22 (26%) | 23 (26%) | - |
| Preop total testosterone (ng/dL) | 178.7 ± 99.3 | 470.7 ± 162.9 | <0.001 |
| Total length of hospital stay (days) | 4.17 ± 10.5 | 1.41 ± 0.93 | 0.031 |
| Postop hemoglobin (ng/dL) | 12.5 ± 2.1 | 13.7 ± 1.7 | <0.001 |
| Postop hematocrit (%) | 37.3 ± 6.1 | 40.9 ± 4.7 | <0.001 |
| 30-day readmission | 0.7 | ||
| No | 77 (90%) | 82 (92%) | - |
| Yes | 9 (10%) | 7 (8%) | - |
| 90-day readmission | 0.6 | ||
| No | 74 (86%) | 80 (90%) | - |
| Yes | 12 (14%) | 9 (10%) | - |
| 180-day readmission | 0.020 | ||
| No | 61 (71%) | 77 (87%) | - |
| Yes | 25 (29%) | 12 (13%) | - |
| 30-day mortality | - | ||
| No | 86 (100%) | 89 (100%) | - |
| 90-day mortality | - | ||
| No | 86 (100%) | 89 (100%) | - |
| 180-day mortality | 0.5 | ||
| No | 84 (98%) | 89 (100%) | - |
| Yes | 2 (2.3%) | 0 (0%) | - |